TG Therapeutics, Inc. (TGTX) Stock
TGTX Key Statistics
About TG Therapeutics, Inc.
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
CEO: Michael S. Weiss. Company website
TGTX — Frequently Asked Questions
What is the TGTX stock price today?
TG Therapeutics, Inc. (TGTX) trades at $56.87, up 0.71% on the day, as of Sep 20, 2026 14:57 UTC.
What is TG Therapeutics, Inc.'s market cap?
TG Therapeutics, Inc. has a market capitalisation of $8.71B, calculated from the live TGTX share price and shares outstanding.
What is the P/E ratio of TGTX?
TGTX trades at a trailing P/E of 20.76, from earnings per share of $2.74 over the last twelve months.
How much revenue does TG Therapeutics, Inc. make?
TG Therapeutics, Inc. generated revenue of $799.54M over the trailing twelve months, which puts the stock at 10.89 times sales.
What is the 52-week range for TGTX?
TGTX has traded between $26.76 and $59.30 over the past 52 weeks, and the last price is 4.1% below that high.
Is TG Therapeutics, Inc. profitable?
Yes. TG Therapeutics, Inc. keeps 55.22% of revenue as net income over the trailing twelve months.
What is the analyst price target for TGTX?
Wall Street analysts rate TGTX Buy, with an average price target of $80.50, 41.6% above the current price.
What sector is TG Therapeutics, Inc. in?
TG Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of TG Therapeutics, Inc.?
Michael S. Weiss is the chief executive of TG Therapeutics, Inc., which employs 399 people.
Where can I track TGTX in real time?
QFI Terminal shows TGTX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See TGTX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open TGTX in Terminal See plans